应交易所要求,美/港股行情延时15分钟展示,下载APP即可免费查看实时行情。
关闭
01093 石药集团
已收盘 02-02 16:08:13
9.140
+0.120
+1.33%
最高
9.350
最低
9.070
成交量
5,783万
今开
9.080
昨收
9.020
日振幅
3.10%
总市值
1,091亿
流通市值
1,091亿
总股本
119.33亿
成交额
5.33亿
换手率
0.48%
流通股本
119.33亿
市净率
--
ROE
--
每股收益
0.00
52周最高
--
52周最低
--
市盈率
--
股息
--
股息收益率
--
ROA
--
分时
五日
日K
周K
月K
北京优虎网络科技有限公司
免责声明:香港交易所资讯服务有限公司、其控股公司及/或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度,但不能保证其绝对准确和可靠,且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任(不管是否侵权法下的责任或合约责任又或其它责任)
资讯
新帖
简况
石药集团(01093):奥曲肽长效注射液获临床试验批准
智通财经网 · 01-19
石药集团(01093):奥曲肽长效注射液获临床试验批准
南向资金1月17日净买入石药集团704.00万股 连续3日增持
自选股智能写手 · 01-18
南向资金1月17日净买入石药集团704.00万股 连续3日增持
新诺威:目前在产石药牌维生素E辅酶Q10软胶囊及石药牌辅酶Q10咀嚼片等产品
每日经济新闻 · 01-12
新诺威:目前在产石药牌维生素E辅酶Q10软胶囊及石药牌辅酶Q10咀嚼片等产品
日内,Paxlovid仿制药概念股活跃,午后,石药集团(01093.HK)温和走强,升约5%
证券之星 · 01-11
日内,Paxlovid仿制药概念股活跃,午后,石药集团(01093.HK)温和走强,升约5%
港股异动 | 石药集团(01093)升5% 公司已完成Paxlovid仿制药BE临床 为国内最早
智通财经 · 01-11
港股异动 | 石药集团(01093)升5% 公司已完成Paxlovid仿制药BE临床 为国内最早
石药集团1月10日获南向资金加仓600.10万股
自选股智能写手 · 01-11
石药集团1月10日获南向资金加仓600.10万股
咖啡因量价齐升 新诺威预计2022年净利润增72.93%-103.44%
证券时报网 · 01-09
咖啡因量价齐升 新诺威预计2022年净利润增72.93%-103.44%
石药集团(01093)附属开发的丁酸氯维地平注射用乳剂获临床试验批准
智通财经 · 01-09
石药集团(01093)附属开发的丁酸氯维地平注射用乳剂获临床试验批准
【券商聚焦】华泰证券维持石药集团(01093)“买入”评级 常规业务企稳且抗疫品种销售提速
凤凰网港股 · 01-06
【券商聚焦】华泰证券维持石药集团(01093)“买入”评级 常规业务企稳且抗疫品种销售提速
石药集团(01093):美洛昔康纳晶注射液获国家药监局批准临床试验
智通财经 · 01-05
石药集团(01093):美洛昔康纳晶注射液获国家药监局批准临床试验
里昂:重申看好中国医疗行业 首选石药集团(01093)等
智通财经 · 01-05
里昂:重申看好中国医疗行业 首选石药集团(01093)等
*里昂重申看好中国医疗行业 首选石药(01093.HK)、国药(01099.HK)、泰格医药(03347.HK)、药明生物(02269.HK)及康方生物(09926.HK)
阿斯达克财经 · 01-05
*里昂重申看好中国医疗行业 首选石药(01093.HK)、国药(01099.HK)、泰格医药(03347.HK)、药明生物(02269.HK)及康方生物(09926.HK)
石药集团(01093):高选择性PRMT5抑制剂SYH2045获临床试验批准
智通财经 · 01-04
石药集团(01093):高选择性PRMT5抑制剂SYH2045获临床试验批准
石药集团盘中异动 临近收盘股价大涨5.05%报8.741港元
自选股智能写手 · 01-04
石药集团盘中异动 临近收盘股价大涨5.05%报8.741港元
石药集团12月30日获南向资金加仓426.80万股
自选股智能写手 · 01-03
石药集团12月30日获南向资金加仓426.80万股
2022港股最后一个交易日:三大指数集体收涨 保险内房股走高
财联社 · 2022-12-30
2022港股最后一个交易日:三大指数集体收涨 保险内房股走高
石药集团(01093):ALMB-0166用于治疗骨关节炎获临床试验批准
智通财经 · 2022-12-29
石药集团(01093):ALMB-0166用于治疗骨关节炎获临床试验批准
格隆汇公告精选(港股)︱华润置地拟124亿元向华夏幸福收购地产资产;康希诺生物公布吸入用及肌注式新冠疫苗近期临床研究成果
格隆汇 · 2022-12-28
格隆汇公告精选(港股)︱华润置地拟124亿元向华夏幸福收购地产资产;康希诺生物公布吸入用及肌注式新冠疫苗近期临床研究成果
石药集团(01093):口服小分子CDK抑制剂SYH2043获临床试验批准
智通财经网 · 2022-12-28
石药集团(01093):口服小分子CDK抑制剂SYH2043获临床试验批准
港股公告掘金 | 这公司附属公司研发的TNFR2全人源抗体药物用于治疗晚期实体瘤获美国临床试验批准 该疗法有望成为治疗晚期实体瘤的一种新策略
智通财经 · 2022-12-23
港股公告掘金 | 这公司附属公司研发的TNFR2全人源抗体药物用于治疗晚期实体瘤获美国临床试验批准 该疗法有望成为治疗晚期实体瘤的一种新策略
加载更多
公司概况
公司名称:
石药集团
所属市场:
SEHK
上市日期:
--
主营业务:
石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门:成药部门、抗生素(中间体及原料药)部门、维生素C(原料药)部门及咖啡因及其他(原料药)部门,分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。
发行价格:
--
{"stockData":{"symbol":"01093","market":"HK","secType":"STK","nameCN":"石药集团","latestPrice":9.14,"timestamp":1675325293011,"preClose":9.02,"halted":0,"volume":57827837,"delay":0,"floatShares":11933219732,"shares":11933219732,"eps":0.54672664,"marketStatus":"已收盘","marketStatusCode":5,"change":0.12,"latestTime":"02-02 16:08:13","open":9.08,"high":9.35,"low":9.07,"amount":533209066,"amplitude":0.031042,"askPrice":9.16,"askSize":108000,"bidPrice":9.14,"bidSize":226000,"shortable":3,"etf":0,"ttmEps":0.5609697068097322,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1675387800000},"adr":0,"listingDate":772128000000,"adjPreClose":9.02,"dividendRate":0.030265,"volumeRatio":1.340999,"lotSize":2000,"spreadScale":0,"tradeCurrency":"HKD","optionSymbol":"CSP.HK"},"requestUrl":"/m/hq/s/01093","defaultTab":"news","newsList":[{"id":"2304614219","title":"石药集团(01093):奥曲肽长效注射液获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2304614219","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2304614219?lang=zh_CN&edition=full","pubTime":"2023-01-19 17:50","pubTimestamp":1674121848,"startTime":"0","endTime":"0","summary":"石药集团(01093)发布公告,公司附属公司石药集团中奇制药技术(石家庄)有限公司...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_22.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_22.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/864942.html","is_publish_highlight":false},{"id":"2304579854","title":"南向资金1月17日净买入石药集团704.00万股 连续3日增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2304579854","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2304579854?lang=zh_CN&edition=full","pubTime":"2023-01-18 09:30","pubTimestamp":1674005449,"startTime":"0","endTime":"0","summary":"1月17日, 南向资金增持石药集团704.00万股,连续3日增持。截止当日收盘,港股通共持有石药集团74934.92万股,占流通股6.27%。石药集团近5个交易日上涨5.78%,港股通累计增持360.18万股;近20个交易日上涨6.77%,港股通累计增持531.52万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301180933558060f9c3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202301180933558060f9c3&s=b","is_publish_highlight":false},{"id":"2302863092","title":"新诺威:目前在产石药牌维生素E辅酶Q10软胶囊及石药牌辅酶Q10咀嚼片等产品","url":"https://stock-news.laohu8.com/highlight/detail?id=2302863092","media":"每日经济新闻","top":-1,"share":"https://www.laohu8.com/m/news/2302863092?lang=zh_CN&edition=full","pubTime":"2023-01-12 17:07","pubTimestamp":1673514445,"startTime":"0","endTime":"0","summary":"每经AI快讯,有投资者在投资者互动平台提问:公司生产辅酶q10吗?新诺威(300765.SZ)1月12日在投资者互动平台表示,公司目前在产石药牌维生素E辅酶Q10软胶囊及石药牌辅酶Q10咀嚼片等产品。(记者 毕陆名)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230112170739824eaffe&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230112170739824eaffe&s=b","is_publish_highlight":false},{"id":"2302519029","title":"日内,Paxlovid仿制药概念股活跃,午后,石药集团(01093.HK)温和走强,升约5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2302519029","media":"证券之星","top":-1,"share":"https://www.laohu8.com/m/news/2302519029?lang=zh_CN&edition=full","pubTime":"2023-01-11 14:40","pubTimestamp":1673419232,"startTime":"0","endTime":"0","summary":"公司是国内最早完成Paxlovid仿制药BE临床的企业,且具有1~2亿人份的原料药及制剂产能。去年9月,石药针对Paxlovid注册了自研产品的生物等效性试验。截至发稿,石药集团涨4.97%,报9.08港元,成交额3.98亿港元。截至2023年1月10日收盘,石药集团报收于8.65元,上涨0.35%,换手率0.51%,成交量6049.6万股,成交额5.18亿元。华泰证券最新一份研报给予石药集团买入评级,目标价12.53。机构评级详情见下表:石药集团港股市值1032.22亿港元,在化学制药行业中排名第2。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://stock.stockstar.com/RB2023011100004623.shtml","is_publish_highlight":false},{"id":"2302229026","title":"港股异动 | 石药集团(01093)升5% 公司已完成Paxlovid仿制药BE临床 为国内最早","url":"https://stock-news.laohu8.com/highlight/detail?id=2302229026","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2302229026?lang=zh_CN&edition=full","pubTime":"2023-01-11 14:22","pubTimestamp":1673418171,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,日内,Paxlovid仿制药概念股活跃,午后,石药集团温和走强,升约5%。公司是国内最早完成Paxlovid仿制药BE临床的企业,且具有1~2亿人份的原料药及制剂产能。去年9月,石药针对Paxlovid注册了自研产品的生物等效性试验。截至发稿,石药集团涨4.97%,报9.08港元,成交额3.98亿港元。去年11月,石药旗下新冠小分子药物“SYHX1901片”获批准,用于治疗重症新冠肺炎成人患者的临床试验。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/860265.html","is_publish_highlight":false},{"id":"2302046491","title":"石药集团1月10日获南向资金加仓600.10万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2302046491","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2302046491?lang=zh_CN&edition=full","pubTime":"2023-01-11 09:30","pubTimestamp":1673400657,"startTime":"0","endTime":"0","summary":"1月10日, 南向资金增持石药集团600.10万股。截止当日收盘,港股通共持有石药集团74574.74万股,占流通股6.24%。港股通增持金额前五个股分别为微盟集团、泡泡玛特、友邦保险、中国移动、中国联通。石药集团近5个交易日上涨3.97%,港股通累计减持501.38万股;近20个交易日上涨1.76%,港股通累计增持5502.85万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023011109341582aff91e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023011109341582aff91e&s=b","is_publish_highlight":false},{"id":"2302072007","title":"咖啡因量价齐升 新诺威预计2022年净利润增72.93%-103.44%","url":"https://stock-news.laohu8.com/highlight/detail?id=2302072007","media":"证券时报网","top":-1,"share":"https://www.laohu8.com/m/news/2302072007?lang=zh_CN&edition=full","pubTime":"2023-01-09 18:34","pubTimestamp":1673260443,"startTime":"0","endTime":"0","summary":"公司表示,咖啡因类产品销售收入及毛利水平均大幅提升,带动公司整体业绩快速增长。公司的主要产品之一为咖啡因,根据公司2021年年报公布的数据,其产能在13000吨。根据wind数据,咖啡因及其盐出口平均单价从2021年底开始大幅上涨,从9-10美元/千克价位跃升至16-17美元/千克。同时,进入2022年后,公司咖啡因主要原材料氰乙酸价格有所回调,价差有所拉大。文章来源:证券时报网咖啡因量价齐升 新诺威预计2022年净利润增72.93%-103.44%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230109183844824cfbcc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20230109183844824cfbcc&s=b","is_publish_highlight":false},{"id":"2302238727","title":"石药集团(01093)附属开发的丁酸氯维地平注射用乳剂获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2302238727","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2302238727?lang=zh_CN&edition=full","pubTime":"2023-01-09 18:12","pubTimestamp":1673259128,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团(01093)公布,集团附属公司石药集团中诺药业(石家庄)有限公司开发的丁酸氯维地平注射用乳剂(50ml:25mg、100ml:50mg)已获得中华人民共和国国家药品监督管理局批准,可以在中国开展临床试验。丁酸氯维地平是一种二氢吡啶类钙通道阻滞剂,适用于在口服降压药不适用或无法取得满意疗效的情况下治疗高血压。该产品为水包油型乳剂,给药方式为静脉输注,可降低动脉血压,其起效快,半衰期短等药理特性可满足高血压急症和围手术期高血压的用药需求。该产品是该集团研发的首个纳米乳剂,其临床试验获批标志着集团的特殊制剂技术平台进一步丰富。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/859189.html","is_publish_highlight":false},{"id":"2301246349","title":"【券商聚焦】华泰证券维持石药集团(01093)“买入”评级 常规业务企稳且抗疫品种销售提速","url":"https://stock-news.laohu8.com/highlight/detail?id=2301246349","media":"凤凰网港股","top":-1,"share":"https://www.laohu8.com/m/news/2301246349?lang=zh_CN&edition=full","pubTime":"2023-01-06 15:31","pubTimestamp":1672990301,"startTime":"0","endTime":"0","summary":"华泰证券发研报指,随着疫情防控优化配套细则陆续落地,石药集团近期在相关领域进展颇丰:1)新冠mRNA疫苗已于2022年12月21日完成4000人的国内三期临床入组;2)SYH2055I/II期患者招募中;3)两退一抗及果维康等疫情急需药品近期销售亮眼。该行认为SYS6006有望获批EUA及新冠小分子药临床持续推进为重要催化,维持“买入”评级。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"source_url":"http://hknews.szfuit.com/newRssInfo/feed?original_id=683e87ab7b150221a1985e501970bffb","is_publish_highlight":false},{"id":"2301423672","title":"石药集团(01093):美洛昔康纳晶注射液获国家药监局批准临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2301423672","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2301423672?lang=zh_CN&edition=full","pubTime":"2023-01-05 16:39","pubTimestamp":1672907952,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团 发布公告,该公司附属公司石药集团中奇制药技术(石家庄)有限公司开发的美洛昔康纳晶注射液已获中华人民共和国国家药品监督管理局批准,可在中国开展临床试验。美洛昔康是一种选择性非甾体抗炎药,国内已上市的口服制剂及普通肌肉注射剂主要用于骨关节炎和类风湿性关节炎等慢性疼痛治疗。该产品作为非阿片类药物,每日仅需给药1次,有望成为治疗成人中重度疼痛更优的药物选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/857637.html","is_publish_highlight":false},{"id":"2301233239","title":"里昂:重申看好中国医疗行业 首选石药集团(01093)等","url":"https://stock-news.laohu8.com/highlight/detail?id=2301233239","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2301233239?lang=zh_CN&edition=full","pubTime":"2023-01-05 15:39","pubTimestamp":1672904399,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,里昂发布研究报告称,今年是中国医疗保健的关键一年。在病人流量预期恢复下,重申看好中国医疗行业,首选石药集团、国药控股、泰格医药、药明生物及康方生物-B等。该行指出,医院就诊率的潜在改善是今年关键的投资主题。报告中称,由于近期受到疫情影响,预计今年内地患者流量暂时同去年类似。展望今年后期,如果病人流量恢复至2019年水平,医院就诊量和住院病人就诊量的同比增长可能超过28%和5%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/857563.html","is_publish_highlight":false},{"id":"2301284633","title":"*里昂重申看好中国医疗行业 首选石药(01093.HK)、国药(01099.HK)、泰格医药(03347.HK)、药明生物(02269.HK)及康方生物(09926.HK)","url":"https://stock-news.laohu8.com/highlight/detail?id=2301284633","media":"阿斯达克财经","top":-1,"share":"https://www.laohu8.com/m/news/2301284633?lang=zh_CN&edition=full","pubTime":"2023-01-05 13:03","pubTimestamp":1672894980,"startTime":"0","endTime":"0","summary":"(港股报价延迟最少十五分钟。沽空资料截至 2023-01-05 12:25。)","market":"hk","thumbnail":"http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg","type":0,"news_type":0,"thumbnails":["http://plib.aastocks.com/aafnnews/image/medialib/20190401142440189_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1236825/latest-news/HK6","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1236825/latest-news/HK6","is_publish_highlight":false},{"id":"2300442163","title":"石药集团(01093):高选择性PRMT5抑制剂SYH2045获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2300442163","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2300442163?lang=zh_CN&edition=full","pubTime":"2023-01-04 18:12","pubTimestamp":1672827127,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团(01093)公布,集团开发的SYH2045已获得中华人民共和国国家药品监督管理局批准,可以在中国开展用于治疗晚期恶性肿瘤的临床试验。公告称,该产品为具有自主知识产权的化药1类新药,是一种高选择性新型蛋白质精氨酸甲基转移酶5(PRMT5)抑制剂。临床前研究显示,该产品通过抑制组蛋白和非组蛋白上精氨酸的甲基化水平调控基因的转录、mRNA剪接、表达、细胞增殖和分化,抑制肿瘤细胞的增殖,发挥抗肿瘤作用。该产品对PRMT5有较高的选择性和强抑制作用,脱靶风险较低,具有优异的体内外活性和良好的安全性,极具临床开发价值。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/857140.html","is_publish_highlight":false},{"id":"2300044537","title":"石药集团盘中异动 临近收盘股价大涨5.05%报8.741港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2300044537","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2300044537?lang=zh_CN&edition=full","pubTime":"2023-01-04 16:01","pubTimestamp":1672819272,"startTime":"0","endTime":"0","summary":"2023年01月04日临近收盘16时01分,石药集团股票出现异动,股价快速上涨5.05%。截至发稿,该股报8.741港元/股,成交量5092.57万股,换手率0.43%,振幅3.49%。资金方面,该股资金流入1.96026亿港元,流出1.47481亿港元。石药集团股票所在的药品行业中,整体涨幅为1.30%。其相关个股中,和黄医药、阿里健康、大健康国际涨幅较大,振幅较大的相关个股有大健康国际、泰凌医药、满贯集团,振幅分别为21.13%、15.56%、13.11%。该公司以“石药”品牌销售其产品。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023010416011282aea34a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023010416011282aea34a&s=b","is_publish_highlight":false},{"id":"2300482440","title":"石药集团12月30日获南向资金加仓426.80万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2300482440","media":"自选股智能写手","top":-1,"share":"https://www.laohu8.com/m/news/2300482440?lang=zh_CN&edition=full","pubTime":"2023-01-03 09:30","pubTimestamp":1672709456,"startTime":"0","endTime":"0","summary":"12月30日, 南向资金增持石药集团426.80万股,连续6日增持。截止当日收盘,港股通共持有石药集团75018.32万股,占流通股6.27%。石药集团近5个交易日下跌0.85%,港股通累计增持804.39万股;近20个交易日下跌17.92%,港股通累计增持5390.56万股。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023010309343482ae4fb1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2023010309343482ae4fb1&s=b","is_publish_highlight":false},{"id":"2295390971","title":"2022港股最后一个交易日:三大指数集体收涨 保险内房股走高","url":"https://stock-news.laohu8.com/highlight/detail?id=2295390971","media":"财联社","top":-1,"share":"https://www.laohu8.com/m/news/2295390971?lang=zh_CN&edition=full","pubTime":"2022-12-30 17:25","pubTimestamp":1672392323,"startTime":"0","endTime":"0","summary":"机构指出,美联储加息预期缓解、外资回流叠加内资抄底、国内疫情防控政策优化、支持房地产融资措施加码等,预计内外部政策的边际变化对港股市场的影响短期仍会发挥作用,因此震荡修复的行情在2023年初料有延续。","market":"sh","thumbnail":"https://img.cls.cn/images/20221230/7NRJ43X9WD.jpg@!thumb_flash","type":0,"news_type":0,"thumbnails":["https://img.cls.cn/images/20221230/7NRJ43X9WD.jpg@!thumb_flash"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://m.cls.cn/depth/1227081","is_publish_highlight":false},{"id":"2295996061","title":"石药集团(01093):ALMB-0166用于治疗骨关节炎获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2295996061","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2295996061?lang=zh_CN&edition=full","pubTime":"2022-12-29 17:37","pubTimestamp":1672306678,"startTime":"0","endTime":"0","summary":"智通财经APP讯,石药集团 公布,集团ALMB-0166用于治疗骨关节炎已获得中华人民共和国国家药品监督管理局批准,可以在中国开展临床试验。临床前研究显示ALMB-0166能够显著地减轻动物骨关节疼痛,以及改善动物软骨组织的病理状况,为从根本上治疗骨关节炎提供了新的潜在疗法。集团将全力以赴推进ALMB-0166在不同适应症的临床研究工作,力争该产品尽快上市。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/854399.html","is_publish_highlight":false},{"id":"2295740936","title":"格隆汇公告精选(港股)︱华润置地拟124亿元向华夏幸福收购地产资产;康希诺生物公布吸入用及肌注式新冠疫苗近期临床研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2295740936","media":"格隆汇","top":-1,"share":"https://www.laohu8.com/m/news/2295740936?lang=zh_CN&edition=full","pubTime":"2022-12-28 23:55","pubTimestamp":1672242906,"startTime":"0","endTime":"0","summary":"远大医药(00512.HK)创新口服小分子抗新冠病毒感染3CL蛋白酶抑制剂GS221的临床试验顺利开展","market":"hk","thumbnail":"https://img7.gelonghui.com/column/2/108.png","type":0,"news_type":0,"thumbnails":["https://img7.gelonghui.com/column/2/108.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"https://www.gelonghui.com/p/571234","is_publish_highlight":false},{"id":"2294860007","title":"石药集团(01093):口服小分子CDK抑制剂SYH2043获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2294860007","media":"智通财经网","top":-1,"share":"https://www.laohu8.com/m/news/2294860007?lang=zh_CN&edition=full","pubTime":"2022-12-28 16:43","pubTimestamp":1672217017,"startTime":"0","endTime":"0","summary":"石药集团(01093)公布,集团开发的SYH2043已获中华人民共和国国家药品监督...","market":"sh","thumbnail":"https://img.zhitongcaijing.com/gonggao/ztcj_announce_34.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/gonggao/ztcj_announce_34.jpeg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/853539.html","is_publish_highlight":false},{"id":"2293555652","title":"港股公告掘金 | 这公司附属公司研发的TNFR2全人源抗体药物用于治疗晚期实体瘤获美国临床试验批准 该疗法有望成为治疗晚期实体瘤的一种新策略","url":"https://stock-news.laohu8.com/highlight/detail?id=2293555652","media":"智通财经","top":-1,"share":"https://www.laohu8.com/m/news/2293555652?lang=zh_CN&edition=full","pubTime":"2022-12-23 08:24","pubTimestamp":1671755070,"startTime":"0","endTime":"0","summary":"石药集团:附属自主研发的全人源抗体药物NBL-020用于治疗晚期实体瘤获美国临床试验批准石药集团公告称,公司附属公司NovaRock Biotherapeutics Limited自主研发的全人源抗体药物 NBL-020的试验性新药申请已获美国食品药品监督管理局批准,可在美国开展用于治疗晚期实体瘤的临床试验。NBL-020是一种抗肿瘤坏死因子2型受体的全人源单克隆抗体。在肿瘤微环境中使用TNFR2抗体抑制高度抑制性的Tregs及MDSCs有望成为治疗晚期实体瘤的一种新策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"source_url":"http://www.zhitongcaijing.com/content/detail/851752.html","is_publish_highlight":false}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.0353},{"period":"1month","weight":0.1},{"period":"3month","weight":-0.0033},{"period":"6month","weight":0.0723},{"period":"1year","weight":-0.0211},{"period":"ytd","weight":0.1}],"websiteUrl":"http://www.cspc.com.hk","compareEarnings":[{"period":"1week","weight":0.0012},{"period":"1month","weight":0.1158},{"period":"3month","weight":0.4389},{"period":"6month","weight":0.0926},{"period":"1year","weight":-0.0727},{"period":"ytd","weight":0.1158}],"name":"石药集团","description":"石药集团有限公司是一家主要从事药品生产和销售的投资控股公司。该公司以“石药”品牌销售其产品。该公司包括四个业务部门:成药部门、抗生素(中间体及原料药)部门、维生素C(原料药)部门及咖啡因及其他(原料药)部门,分别从事生产及销售相关药品业务。该公司的成药包括抗生素、心脑血管用药、糖尿病用药、精神神经用药、抗肿瘤用药及中医药产品。该公司还通过其子公司从事提供药品研发服务及污水及药物副产品处理业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.551724,"avgChangeRate":0.015601},{"month":2,"riseRate":0.758621,"avgChangeRate":0.101181},{"month":3,"riseRate":0.464286,"avgChangeRate":0.024031},{"month":4,"riseRate":0.571429,"avgChangeRate":0.056961},{"month":5,"riseRate":0.607143,"avgChangeRate":0.045162},{"month":6,"riseRate":0.321429,"avgChangeRate":0.006761},{"month":7,"riseRate":0.37931,"avgChangeRate":0.004432},{"month":8,"riseRate":0.448276,"avgChangeRate":0.019201},{"month":9,"riseRate":0.517241,"avgChangeRate":-0.006033},{"month":10,"riseRate":0.586207,"avgChangeRate":0.011883},{"month":11,"riseRate":0.448276,"avgChangeRate":0.008663},{"month":12,"riseRate":0.482759,"avgChangeRate":-0.016104}],"exchange":"SEHK","nameEN":"CSPC PHARMA","compareStock":{"symbol":"HSI","name":"恒生指数"}},"APP":{"userAgent":"CCBot/2.0 (https://commoncrawl.org/faq/)","isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.11.11","shortVersion":"4.11.11","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"石药集团,01093,石药集团股票,石药集团股票老虎,石药集团股票老虎国际,石药集团行情,石药集团股票行情,石药集团股价,石药集团股市,石药集团股票价格,石药集团股票交易,石药集团股票购买,石药集团股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"石药集团(01093)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供石药集团(01093)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}